PSS25 Validation of the Patient Benefit Index (PBI) for the Assessment of Patient-Defined Benefit in the Treatment of Psoriasis  by Feuerhahn, J. et al.
U.S. dollars. Incremental cost-effectiveness ratios (ICERs) were calculated compar-
ing the least costly alternative to the next most costly strategy. Deterministic and
probabilistic sensitivity analyses were conducted. RESULTS: Ranibizumab demon-
strated superior efficacy relative to other strategies in both BRVO and CRVO but was
most costly ($26,732 and $32,850; BRVO and CRVO, respectively). Other strategy
costs ranged from $10,622 (observation in BRVO) to $16,090 (dexamethasone intra-
vitreal implant in CRVO patients). QALYs were greatest for ranibizumab (6.75 and
6.10; BRVO and CRVO, respectively) compared to a range of 4.88 (observation in
CRVO) to 5.93 (laser in BRVO). Dexamethasone intravitreal implant was dominated
in BRVO as was no treatment in CRVO. ICERs for ranibizumab were favorable
($19,270/QALY vs laser in BRVO; $34,204/QALY vs dexamethasone intravitreal im-
plant in CRVO). At a threshold of $50,000/QALY, probabilistic analyses suggested
ranibizumab to be cost effective in 99.7% (BRVO) and 88.3% (CRVO) of simulations.
CONCLUSIONS: In patients with ME secondary to BRVO or CRVO, ranibizumab is a
cost-effective treatment alternative.
SENSORY SYSTEMS DISORDERS - Patient-Reported Outcomes & Patient
Preference Studies
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OBJECTIVES: Retinal vein occlusion (RVO) is the second most common vascular
disorder of the retina, affecting approximately 28,000 new patients every year in
Canada, but little is known about their health utility. A Canadian Observational
Utility Study was conducted to estimate utility values for RVO patients with differ-
ent levels of visual acuity (VA). METHODS: A total of 202 participants with RVO,
where 37% had CRVO and 63% had BRVO, were enrolled from 20 sites across Can-
ada. Participantss had RVO in either their best-seeing eye (17%) or worse-seeing eye
(83%). Spectacle corrected VA was measured and patient health utility was col-
lected using the Health Utilities Index questionnaire (HUI3). VA was recorded as a
fraction (Snellen Score) and the value of this fraction was expressed as logMAR. A
linear regression model was used to predict utility values from logMAR in the
affected eye adjusting for key clinical covariates (age, duration of disease, logMAR
in fellow eye). The baseline characteristics of participants from randomized con-
trolled clinical trials (BRAVO, CRUISE) were used to generate predicted health util-
ities relevant in the context of these studies. RESULTS: For the 202 participants
(ages 39 to 92, median 72) the mean (SD) HUI utility value was 0.80 (0.20), ranging
from 0.18 to 1 (n169) and logMAR score was 0.62 (0.42), ranging from 0 to 1.60
(n202). The correlation between VA and utility was significant (r -0.21, p0.004,
n169) and the regression model indicated that a one unit increase in logMAR
score was associated with 0.085 unit decrease in utility. Based on the regression
model, HUI-based utilities decrease from 0.87 (logMAR -0.15) to 0.74 (logMAR 1.45)
for typical patients in the randomized studies (mean age67, logMAR fellow
eye0.09, disease duration3.4 months). CONCLUSIONS: RVO is a debilitating
ophthalmologic condition leading to reduced health utility with worsening of vi-
sual acuity.
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OBJECTIVES: Despite well-documented safety and tolerability issues associated
with traditional systemic therapies, many moderate and severe psoriasis patients
remain on these therapies. This analysis aims to assess levels of satisfaction and
quality of life in a biologic-eligible patient population currently receiving tradi-
tional systemic therapy. METHODS: Data were extracted from the Adelphi Real
World Psoriasis Disease-Specific Programme® (DSP), a cross-sectional survey of
dermatologists and their patients conducted in early 2011 in France, Germany,
Italy, Spain and the UK. Each dermatologist completed a comprehensive patient
record form (PRF) for their seven most recently seen psoriasis patients who met the
inclusion criteria. Patients were also invited to fill out a self-completion question-
naire, which included questions on satisfaction with treatment and various vali-
dated Health Related Quality of Life (HRQoL) instruments (EQ5D and DLQI). Patients
inclusion criteria were based on being eligible to receive biologic therapy; defined
by Body Surface Area ever exceeding 10%, ever having moderate or severe disease
(in the opinion of the physician), or ever having received a traditional systemic or
biologic treatment. RESULTS: Patient reported satisfaction levels show 58.7%
(n261) satisfied (SAT) and 41.3% (n184) dissatisfied (DIS) with current systemic
treatment. Analyses also suggested lower QoL amongst dissatisfied patients (all
reported figures have P-values 0.01; mean differences (MD) shown account for
confounding factors; age, severity and BSA). EQ-5D and DLQI scores indicated
poorer QoL amongst dissatisfied systemic patients, SAT 0.841 v DIS 0.672 (MD 0.124)
and SAT 5.14 v DIS 9.68 (MD 3.25), respectively. CONCLUSIONS: The analysis con-
ducted indicates that a number of patients remain dissatisfied with systemic treat-
ment. This dissatisfaction is associated with lower QoL, measured by both generic
and disease specific instruments. There is scope for additional investigation to
determine if alternate treatment pathways could improve both treatment satisfac-
tion and QoL for this patient group.
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OBJECTIVES: Despite well-documented safety and tolerability issues associated
with traditional systemic therapies, there remain barriers to biologic uptake in
many moderate and severe psoriasis patients. This analysis assesses the level of
treatment satisfaction with patient burden, namely work/activity impairment and
emotional wellbeing, in 445 patients currently receiving traditional systemic ther-
apy who are eligible for, but not receiving, biologic therapy. METHODS: Data were
extracted from the Adelphi Real World Psoriasis Disease-Specific Programme®, a
cross-sectional survey of 292 dermatologists and their patients conducted in early
2011 in France, Germany, Italy, Spain and the UK. Each dermatologist completed
patient record forms for their seven most recently seen patients. Patients were
invited to complete a questionnaire, including questions on satisfaction and vali-
dated instruments WPAI (Work Productivity and Activity Impairment) & PHQ9 (per-
sonal health questionnaire). Patient inclusion criteria were based on being eligible
to receive biologic therapy defined by: Body Surface Area ever exceeding 10%, ever
having moderate or severe disease (physician assessment), or ever having received
a traditional systemic or biologic treatment.RESULTS: Patient reported satisfaction
levels show 58.7% (n261) satisfied (SAT) and 41.3% (n184) dissatisfied (DIS) with
current treatment. Results from the WPAI questionnaire (n177) implied worse
average results for those dissatisfied with current treatment, DIS 30.40 v SAT 17.12
(Mean Difference (MD) -10.53). PHQ9 (n442) also found worse outcomes for dis-
satisfied patients; SAT 3.57 v DIS 6.01 (MD -1.94). All reported figures have P-values
0.05; MD incorporate confounding factors; age, severity and BSA. CONCLUSIONS:
This analysis provides insight into the divergence in burden of disease amongst
psoriasis patients, with patients dissatisfied with current systematic regimen suf-
fering greater implied levels of burden than satisfied patients. There is scope to
develop this further to better understand the implications of treatment dissatis-
faction in this population.
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OBJECTIVES: Patient-relevant endpoints play an important role in Health Technol-
ogy Assessment (HTA). There is a need to prioritize these endpoints according to
patients’ preferences. Our aim was to investigate how glaucoma patients prioritize
different aspects of their treatment including patient-relevant endpoints.
METHODS: The study included a feasibility test and the completion of a specific
questionnaire at the ophthalmology clinic of Bonn. Patients rated the importance
of different aspects of glaucoma treatment by a pairwise comparison. Relative
weights were generated for each aspect by Analytic Hierarchy Process (AHP), a
multi-criteria decision analysis method using matrix algebra. . Additionally the
EQ-5D was applied to stratify the patients into subgroups according to their stated
utility. RESULTS: The AHP yielded the following results (Weight, Mean, SD, CI) by
downwards order: 1. Autonomy (0.394, 0.371  0.145, 0.311 - 0.431), subdivided in
household chores (0.239, 0.275  0.258, 0.168 - 0.381) and outdoor mobility (0.761,
0.725 0.258, 0.619 - 0.832). 2. Reading and seeing details (0.229, 0.212 0.123, 0.161
- 0.263). 3. Darkness and glare (0.153, 0.165 0.111, 0.119 - 0.211). 4. Peripheral vision
(0.089, 0.085 0.058, 0.061 - 0.109). 5. Side effects (0.088, 0.115 0.131, 0.060 - 0.168),
and 6. Treatment-related burden (0.047, 0.052  0.06, 0.027 - 0.076). The observed
inconsistency reached a consistency ratio of 0.04 and did not exceed the limit of 0.1.
Subgroup analyses according to the EQ-5D stratification showed adaptation effects
and loss aversion. CONCLUSIONS: AHP can be used in HTA to give a quantitative
dimension to patients’ preferences for treatment aspects. Preference elicitation
could provide important information at various stages of HTA and challenge opin-
ions on the importance of treatment aspects or endpoints.
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OBJECTIVES: Empirical evidence for the efficacy of drugs and therapeutic proce-
dures has become crucial for reimbursement and for use in praxis. Beyond that,
assessment of patient benefit from the patient’s perspective is of particular rele-
vance. The PBI for skin diseases is a validated instrument developed to measure
patient-relevant benefits in dermatology. So far, no specific validation data on such
an instrument for psoriasis have been published. Objective of this study was the
validation of PBI specifically for psoriasis treatment. METHODS: Patient-relevant
treatment needs were recorded with the “Patient Needs Questionnaire” (PNQ) and
patient benefits from treatment were assessed using the “Patient Benefit Question-
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naire” (PBQ), both containing identical items with different wording. Data were
obtained from two studies, one being a cross-sectional study on n2,009 patients,
the other a prospective observational therapeutic study on n93 patients. Treat-
ment goals and benefits were used to calculate the overall preference-based Patient
Benefit Index (PBI). RESULTS: In both studies, the PNQ showed a variety of high
therapeutic needs from the perspective of the psoriasis patients. The PBQ ques-
tionnaire revealed that under routine treatment only a part of the patient-defined
goal were achieved. The resulting PBI depended on the treatment applied. Higher
values were observed in systemic treatments, in particular in biologics. The PBI was
feasible with a rate of missing values 1.5% in PNQ and 2.0% in PBQ. The sub-
scales of the PBI were internally consistent (Cronbach’s alpha 0.68 – 0.87). The PBI
showed satisfying convergent validity with respect to correlation with changes in
QoL (delta DLQI) and PASI. Moreover, correlation with separate single items on
treatment benefit (anchoring variables) was markedly high (r0.75, r0.65,
p0.001). CONCLUSIONS: The Patient Benefit Index (PBI) is a valid, reliable and
suitable instrument for the assessment of patient-reported benefit in the treat-
ment of psoriasis.
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OBJECTIVES: Although there are a range of established outcomes measures for
psoriasis in general, there has been a lack of valid instruments for nail psoriasis
(NPso). Therefore, we developed and validated the three-component tool “Nail
Assessment in Psoriasis and Psoriatic Arthritis” (NAPPA) including health-related
quality of life (NAPPA-QoL), patient-relevant treatment benefit (NAPPA-PBI) and
clinical severity (NAPPA-CLIN). METHODS: The NAPPA tool was developed by a
multinational expert group involving dermatologists, psychologists, statisticians,
and patients. Development included the following steps: 1) Open item collection on
patient-relevant impairments and needs in n120 patients in 2 countries (D, USA);
2) item development by an expert panel including patients; 3) double forward and
backward translations with subsequent translators’ and developers’ conferences;
4) feasibility testing of the pilot questionnaire in n55 patients in 4 countries (D,
USA, Canada, UK) with subsequent questionnaire refinement; 5) longitudinal fea-
sibility and validation study in n203 patients from 6 countries (Germany, USA,
Denmark, Japan, Italy, Spain). RESULTS: Open item collection generated 692 single
items with redundant content which could be condensed to 20 items for the
NAPPA-QoL and 24 items for the NAPPA-PBI. Most patients rated the final question-
naires as feasible, i.e. the purpose was clear to them (95.0%), instructions and
questions were comprehensible (83.6% / 89.1%), and all relevant areas were covered
(87.1%). NAPPA-QoL and -PBI correlated moderately with clinical outcomes (PASI,
NAPSI) but markedly with other QoL questionnaires (EQ-5D, DLQI). Sensitivity to
change and internal consistency were good. Clinical severity (NAPPA-CLIN) was
measured with a two-digit solution which correlated highly (r0.9) with NAPSI but
which can be assessed much more time-efficiently. CONCLUSIONS:With the mod-
ular NAPPA outcomes tool, clinical and patient-reported outcomes in nail psoriasis
can be measured validly and reliably. Thus, it can be recommended for usage in
international clinical studies and daily practice.
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DO SCARS IMPACT BEYOND JUST APPEARANCE? A REPORT OF THE CONTENT
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OBJECTIVES: Currently available scar assessment tools focus on the appearance
and symptoms of scars but avoid the complete scar experience. Additionally, ex-
isting instruments lack evidence or documentation (or both) of their development
(e.g., content validity) and performance (e.g., reliability, construct-related validity,
and responsiveness), and it is unlikely they would meet current regulatory require-
ments for labeling. The objective of the present work was to conduct qualitative
research with patients to better understand scar appearance, symptoms, and im-
pacts, and to use those results to inform the development of a content-valid PRO
instrument for use in clinical trials. METHODS: Eight physicians (3 dermatologists
and 5 plastic surgeons) recruited subjects to participate in the CE research activi-
ties. Each subject (aged 18 to 65) was required to have a linear surgical (cosmetic or
non-cosmetic) scar below the neck. Subjects with burn scars were excluded as were
subjects with significant medical comorbidities. The interviews were conducted in
multiple cities in the United States, transcribed, and used to derive the scar ques-
tionnaire items. RESULTS: A total of 43 interviews across five surgery types were
conducted to elicit information regarding their experiences with their disfiguring
scar. During the CE interviews, the most important and relevant concepts patients
used to describe scar appearance were color, size (height, width, thickness), and
texture. The most important and relevant scar symptom concepts reported were
itchiness and pain. The most important, relevant, and bothersome scar impact
concepts were limitations of wearing certain clothing and feeling self-conscious,
sad, and less attractive because of the scar. CONCLUSIONS: The CE interviews
provided rich information about how patients perceive and experience their scars
which extends beyond the typical appearance dimensions. This work is fundamen-
tal in providing the basis for the conceptual framework of the scar experience and
the first steps in the development of the PR-SEQ.
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OBJECTIVES:We describe Week 52 quality of life outcomes following immediate or
gradual transition to ustekinumab in psoriasis patients with inadequate response
to methotrexate in the Phase IV TRANSIT study (NCT01059773). METHODS: In this
52-week, open-label trial, 490 patients with moderate-to-severe plaque psoriasis
despite treatment with methotrexate (10–25mg/week for 8 weeks) were ran-
domised 1:1 to ustekinumab with immediate cessation of methotrexate (Arm1), or
4 weeks’ overlap with decreasing methotrexate dose (Arm2). Ustekinumab was
administered according to label: 45mg in patients 100kg or 90mg if 100kg. Pa-
tients 100kg not achieving adequate response (Psoriasis Area Severity Index de-
crease from baseline 75% [PASI 75]) at Weeks 28 or 40 were dose escalated to
90mg. RESULTS: A total of 244 patients were treated in Arm1 and 245 in Arm2; 92%
and 90%, respectively, completed 52 weeks’ therapy. Median baseline Dermatology
Life Quality Index (DLQI) was 8 and 9 in Arms1 and 2, respectively, decreasing to 1
(both arms) at Weeks 16 and 52. At Week 52 in Arms1 and 2, respectively, 61% and
62% of patients had a DLQI reduction 5 points; 62% and 67% had DLQI 0 or 1.
Median DLQI scores were low at Week 28 among patients who dose escalated;
further improvements were seen by Week 52. Median EuroQOL-5D Visual Analogue
Scale improved from baseline to Week 52, respectively: 70.0 (IQR 50.0–80.0) to 85.0
(IQR 70.0–95.0) in Arm1, and 70.0 (IQR 50.0–85.0) to 85.0 (IQR 79.5–95.0) in Arm2.
Median Hospital Anxiety and Depression Scale (HADS) Anxiety and Depression
scores also improved from baseline to Week 52. CONCLUSIONS: In patients with
moderate-to-severe psoriasis, ustekinumab use was associated with clinically rel-
evant improvements in patient-reported outcomes, irrespective of whether pa-
tients were transitioned with immediate or gradual cessation of methotrexate.
Improvements at Week 16 were sustained to 52 weeks of ustekinumab therapy.
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VISUAL ACUITY AMONG PATIENTS WITH DIABETIC MACULAR EDEMA:
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OBJECTIVES: To investigate whether a 1-line (5 letters) average change in best
corrected visual acuity (BCVA) is associated with changes in health-related quality
of life (HRQoL) in patients with diabetic macular edema (DME). METHODS: Data
from a 12-month randomized trial of dexamethasone intravitreal implant plus
laser or laser alone for DME were analyzed. HRQoL was assessed by the National
Eye Institute 25-Item Visual Function Questionnaire (VFQ-25). Patients were cate-
gorized into groups based on time-weighted average BCVA change from baseline:
worsened (	BCVA -5), no change (-5 	BCVA5) and improved (	BCVA5). Av-
erage change in VFQ-25 composite score and 11 subscales were compared using
ANCOVA analysis controlling for baseline BCVA and VFQ-25 scores. Proportions of
patients achieving 5-point improvement in VFQ-25 composite score and 4 sub-
scales closely associated with central vision (general vision, near activities, distant
activities, and mental health) were also compared. Similar analyses were con-
ducted for subgroups of better-seeing eye (BSE) and worse-seeing eye (WSE) pa-
tients, respectively. RESULTS: A total of 252 (18.3% BSE and 81.7% WSE) patients
had a mean VFQ-25 composite score of 69.1 at baseline. Compared to the no change
BCVA group, the improved group had 3.2-6.7 points (p0.048) greater average
changes in VFQ-25 composite score and 4 subscales (general vision, near activities,
dependency, and driving ); the corresponding differences were greater (10.2-18.3
points, p0.019) among BSE patients except in general vision. The worsened, no
change, and improved BCVA groups showed a statistically different (p0.038) and
increasing trend in achieving 5-point improvement in the 4 VFQ-25 subscales
examined except in distant activities. CONCLUSIONS: Previous literature based on
BSE visual acuity has defined minimally important differences in VFQ-25 score
ranging from 3 to 5 points. The current study suggests a 1-line average improve-
ment in BCVA was associated with clinically meaningful changes in HRQoL among
DME patients.
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